Catalent
| Company type | Private |
|---|---|
| NYSE: CTLT (2014–2024) | |
| Industry | Pharmaceuticals |
| Predecessor | Cardinal Health PTS |
| Founded | 2007 |
| Headquarters | Somerset, New Jersey, U.S. |
Number of locations | 53 (2024) |
Key people |
|
| Services | Drug pre-formulation, formulation, analytical testing, clinical and commercial manufacturing, clinical packaging and supply chain, regulatory consulting |
| Revenue | US$4.38 billion (2024) |
| US$−749 million (2024) | |
| US$−1.04 billion (2024) | |
| Total assets | US$9.75 billion (2024) |
| Total equity | US$3.60 billion (2024) |
Number of employees | 16,900 (2024) |
| Parent | Novo Holdings A/S |
| Website | catalent |
| Footnotes / references Financials as of June 30, 2024. | |
Catalent, Inc. (Catalent Pharma Solutions), is an American multinational company, and a subsidiary of Novo Holdings A/S since 2024. It is headquartered in Somerset, New Jersey. It is a provider of drug delivery technologies, drug development, drug manufacturing, biologics, gene therapy, and consumer health products. It has over 50 facilities on four continents and has supported more than half the products approved by the Food and Drug Administration in the last ten years. Annually, it produces 70 billion doses for 8,000 products. The company's major customers include Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Haleon, Novo Nordisk, Moderna, Pfizer, and Sarepta Therapeutics.